BRPI0117338A2 - método para produzir células desmontaveis - Google Patents

método para produzir células desmontaveis

Info

Publication number
BRPI0117338A2
BRPI0117338A2 BR0117338A BR0117338A BRPI0117338A2 BR PI0117338 A2 BRPI0117338 A2 BR PI0117338A2 BR 0117338 A BR0117338 A BR 0117338A BR 0117338 A BR0117338 A BR 0117338A BR PI0117338 A2 BRPI0117338 A2 BR PI0117338A2
Authority
BR
Brazil
Prior art keywords
rna
dsrna
rnai
sequence
target rna
Prior art date
Application number
BR0117338A
Other languages
English (en)
Other versions
BRPI0117338B1 (pt
Inventor
David P Bartel
Phillip A Sharp
Phillip D Zamore
Thomas Tuschl
Original Assignee
Massachusetts Inst Technology
Max Planck Gesellschaft
Univ Massachusetts Medical
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41655850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0117338(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology, Max Planck Gesellschaft, Univ Massachusetts Medical, Whitehead Biomedical Inst filed Critical Massachusetts Inst Technology
Priority claimed from BR0107536A external-priority patent/BR0107536A/pt
Publication of BRPI0117338A2 publication Critical patent/BRPI0117338A2/pt
Publication of BRPI0117338B1 publication Critical patent/BRPI0117338B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0117338A 2000-03-30 2001-03-30 método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada BRPI0117338B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19359400P 2000-03-30 2000-03-30
EP00126325 2000-12-01
US26523201P 2001-01-31 2001-01-31
BR0107536A BR0107536A (pt) 2000-03-30 2001-03-30 Rna isolado, extrato solúvel, método para produzir rna de cerca de 21 a cerca de 23 nucleotìdeos de comprimento; dna isolado
PCT/US2001/010188 WO2001075164A2 (en) 2000-03-30 2001-03-30 Rna sequence-specific mediators of rna interference

Publications (2)

Publication Number Publication Date
BRPI0117338A2 true BRPI0117338A2 (pt) 2011-08-02
BRPI0117338B1 BRPI0117338B1 (pt) 2016-06-21

Family

ID=41655850

Family Applications (4)

Application Number Title Priority Date Filing Date
BRPI0117340A BRPI0117340B1 (pt) 2000-03-30 2001-03-30 método para examinar a função de um gene em uma célula in vitro
BRPI0117341A BRPI0117341B1 (pt) 2000-03-30 2001-03-30 método para avaliar um agente agindo em um produto de gene, método para avaliar se um produto de gene é um alvo adequado para descoberta de drogas e método para avaliar se um produto de gene é um alvo adequado para avaliar a habilidade de um agente agir no produto de gene
BRPI0117338A BRPI0117338B1 (pt) 2000-03-30 2001-03-30 método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada
BRPI0117339A BRPI0117339B1 (pt) 2000-03-30 2001-03-30 método para identificar sítios alvos dentro de mrna que sejam eficientemente clivados pelo processo rnai, e método para identificar rnas de 21-23 nt que medeiam eficientemente rnai

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0117340A BRPI0117340B1 (pt) 2000-03-30 2001-03-30 método para examinar a função de um gene em uma célula in vitro
BRPI0117341A BRPI0117341B1 (pt) 2000-03-30 2001-03-30 método para avaliar um agente agindo em um produto de gene, método para avaliar se um produto de gene é um alvo adequado para descoberta de drogas e método para avaliar se um produto de gene é um alvo adequado para avaliar a habilidade de um agente agir no produto de gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0117339A BRPI0117339B1 (pt) 2000-03-30 2001-03-30 método para identificar sítios alvos dentro de mrna que sejam eficientemente clivados pelo processo rnai, e método para identificar rnas de 21-23 nt que medeiam eficientemente rnai

Country Status (11)

Country Link
EP (7) EP2796553B1 (pt)
CN (2) CN101643789B (pt)
AT (1) ATE542899T1 (pt)
BR (4) BRPI0117340B1 (pt)
CA (1) CA2791831C (pt)
DK (7) DK2345742T3 (pt)
ES (9) ES2461765T3 (pt)
LT (1) LT2813582T (pt)
PL (1) PL218881B1 (pt)
PT (8) PT2360253E (pt)
SI (4) SI2813582T1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10876121B2 (en) 2016-04-01 2020-12-29 Avidity Biosciences, Inc. EGFR nucleic acids and uses thereof
WO2017173297A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US10858656B2 (en) 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
DE102018001134A1 (de) * 2017-06-26 2018-12-27 Martin-Luther-Universität Halle-Wittenberg Methode zur gezielten Identifizierung hocheffizienter "small interfering RNAs" ("eRNAs") zur Anwendung in Pflanzen und anderen Zielorganismen
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198885A (ja) 1983-04-25 1984-11-10 Nec Corp 圧電アクチェータ励振回路
US5652355A (en) † 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
EP0743859A4 (en) † 1993-11-16 1998-10-21 Genta Inc CHEMICAL OLIGONUCLEOSIDE COMPOUNDS
US6506559B1 (en) † 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2326823A1 (en) † 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003526367A (ja) * 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Rna干渉の方法とrna干渉組成物
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子

Also Published As

Publication number Publication date
CA2791831C (en) 2015-06-23
EP2813582A1 (en) 2014-12-17
BRPI0117341B1 (pt) 2016-06-21
ES2461715T3 (es) 2014-05-21
EP2796553B1 (en) 2019-06-19
PL218881B1 (pl) 2015-02-27
EP2348134B1 (en) 2014-04-16
ES2461765T3 (es) 2014-05-21
SI2348133T1 (sl) 2014-11-28
PT2351852E (pt) 2014-01-03
CA2791831A1 (en) 2002-06-06
BRPI0117341A2 (pt) 2011-08-02
BRPI0117339B1 (pt) 2016-03-15
DK2028278T3 (da) 2014-06-23
ES2632957T3 (es) 2017-09-18
PT2348133E (pt) 2014-10-14
DK2361981T4 (da) 2019-05-13
PT2345742E (pt) 2014-09-03
EP2360253A1 (en) 2011-08-24
DK2351852T3 (da) 2014-01-06
PT2361981E (pt) 2013-06-12
CN101654672B (zh) 2013-06-05
LT2813582T (lt) 2017-07-25
ES2437390T3 (es) 2014-01-10
DK2348134T3 (da) 2014-07-14
CN101643789B (zh) 2013-04-24
SI2813582T1 (sl) 2017-08-31
CN101654672A (zh) 2010-02-24
PT2348134E (pt) 2014-07-16
PT2028278E (pt) 2014-05-28
EP2351852B2 (en) 2020-07-01
ES2500923T3 (es) 2014-10-01
EP2361981A1 (en) 2011-08-31
ES2380171T3 (es) 2012-05-09
SI2351852T1 (sl) 2013-12-31
EP2361981B1 (en) 2013-03-06
SI2348134T1 (sl) 2014-08-29
EP2796553A1 (en) 2014-10-29
BRPI0117338B1 (pt) 2016-06-21
ES2410907T3 (es) 2013-07-03
EP3199631B1 (en) 2019-01-30
DK2348133T3 (da) 2014-10-13
ES2437390T5 (es) 2021-02-05
SI2351852T2 (sl) 2020-10-30
ES2462716T3 (es) 2014-05-26
CN101643789A (zh) 2010-02-10
DK2345742T3 (da) 2014-09-15
PT2813582T (pt) 2017-07-17
PT2360253E (pt) 2014-05-29
ES2498747T3 (es) 2014-09-25
EP2361981B2 (en) 2019-01-23
ATE542899T1 (de) 2012-02-15
BRPI0117340B1 (pt) 2016-10-18
EP2351852B1 (en) 2013-10-02
EP2813582B1 (en) 2017-04-12
CN101654673A (zh) 2010-02-24
EP3199631A1 (en) 2017-08-02
EP2360253B1 (en) 2014-03-19
EP2348134A1 (en) 2011-07-27
DK2351852T4 (da) 2020-08-24
ES2410907T5 (es) 2019-08-20
DK2361981T3 (da) 2013-06-24
EP2351852A1 (en) 2011-08-03
DK2360253T3 (da) 2014-06-16

Similar Documents

Publication Publication Date Title
LTPA2021005I1 (pt)
DK1606406T4 (da) Short Interfering RNA (siRNA) Analogues
PT2360253E (pt) Métodos de produção de células ou organismos knockdown através de interferência por rna com mediadores de rna específicos de sequência e usos dos mesmos
Ochi et al. Gene silencing by 2′-O-methyldithiomethyl-modified siRNA, a prodrug-type siRNA responsive to reducing environment
CY1117311T1 (el) Μικρα rna μορια που προκαλουν παρεμβαση rna

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/06/2016, OBSERVADAS AS CONDICOES LEGAIS.